Replication priority of hepatitis C virus genotype 2a in a Chinese cohort
Background and Aim: HCV genotypes have been documented in clinical patients.The goal of this study is to learn viral replication capacity of different HCV genotypes in human body.Methods: 491 otherwise healthy Chinese blood donors with positive HCV antibody reaction were employed in the study.These subjects were not being treated with antiviral drugs before.HCV genotyping was determined followed by serum viral load quantification.Serum antibody reaction against HCV Core,NS3,NS4 and NS5 epitope antigens was analyzed,respectively,for each of the genotypes.Results: Genotyping analysis showed that among these individuals 6.7% was infected with genotype 1a,41.5% with 1b,36.0% with 2a,6.7% with 2b,2.6% with 3a,1.8% with 3b,2.4% with 6 and 2.0% unidentified.Genotype 1b and 2a were the predominant ones in this Chinese cohort,causing 77.6% HCV infection.Among the genotype groups,individuals infected with genotype 2a had a HCV RNA viral load (108copies/ml) over 100-fold (2.3log) higher than that infected with other genotypes (104-105copies/ml),indicating a replication priority of genotype 2a.There is no correlation between HCV genotype and antibody response against HCV Core,NS3,NS4 and NS5 epitope antigens.It appears that the amplification advantage of genotype 2a results from its nature of favorable interaction with host cellular environment.Conclusions: HCV genotype 1b and 2a are both the predominant genotypes in China; of the seven HCV subtypes analyzed genotype 2a possesses a significant replication priority in this Chinese cohort.
HCV genotype viral load antibody response
Zhen Yang Yong-Xin Yu Hong-Zhong Zhang Gui-Fang Shang Jia-Liang Gao Zong-Gen Peng Jian-Dong Jiang
Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical Co National Institute for the Control of Pharmaceutical and Biological Products,Beijing,100050,China Langfang Blood Center,LangFang,065000,Hebei,China Shenzhen Blood Center,Shenzhen,518035,Guangdong,China Chengdu Blood Center,Chengdu,610041,Sichuan,China Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical Co
国内会议
南京
英文
1-10
2012-11-01（万方平台首次上网日期，不代表论文的发表时间）